2024-520342-28-00撤回1 期
Multicenter, open-label single arm phase I study evaluating the safety and efficacy of combined MB-CART19.1-IBK cells and the 2nd generation BTK-inhibitor Zanubrutinib in relapsed or refractory PCNSL "Zanubrutinib and CAR T cells in R/R PCNSL: Z-CARP-Study" A prospective non-randomized multicenter phase I study
Medizinische Universitaet Innsbruck2 个研究点 分布在 2 个国家目标入组 5 人开始时间: 2026年10月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 5
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
University Hospital for Internal Medicine V (Haematology and Oncology)
Scientific
Medizinische Universitaet Innsbruck
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapyAdvanced or metastatic solid tumours2026-526116-36-00Pliant Therapeutics Inc.15
招募中
1 期
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors2025-521702-18-00Novartis Pharma AG27
招募中
不适用
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors (CFML539A12101)jRCT20312602487
尚未招募
不适用
An open-label, multicenter, single arm study evaluating the efficacy and safety of PRM-001 in the treatment of Crows Feet Lines(CFLs)on the sides of the eyes in Japanese subjectsCrows Feet LinesjRCT2032260114142
进行中（未招募）
1 期
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors2024-513716-95-00Nec Oncoimmunity AS6